Sanofi (NASDAQ:SNY) Shares Bought by Baker Ellis Asset Management LLC

Baker Ellis Asset Management LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 7.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,780 shares of the company's stock after acquiring an additional 6,872 shares during the quarter. Baker Ellis Asset Management LLC's holdings in Sanofi were worth $5,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. McClarren Financial Advisors Inc. lifted its position in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Bessemer Group Inc. increased its holdings in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Sanofi during the fourth quarter valued at $31,000. Sierra Ocean LLC bought a new position in shares of Sanofi during the fourth quarter valued at $44,000. Finally, UMB Bank n.a. increased its holdings in shares of Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after acquiring an additional 264 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 2.3%

Sanofi stock traded up $1.13 during mid-day trading on Thursday, hitting $50.83. The company's stock had a trading volume of 1,947,349 shares, compared to its average volume of 2,387,302. The company has a 50 day moving average of $51.49 and a 200-day moving average of $52.00. The stock has a market cap of $124.66 billion, a PE ratio of 20.41, a P/E/G ratio of 1.01 and a beta of 0.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the company earned $1.78 EPS. The business's revenue was down 11.0% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. The ex-dividend date of this dividend is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Sanofi presently has an average rating of "Buy" and an average price target of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.